NCT07262762Completed
Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
A Post-marketing Real-world Study for Evaluating Effectiveness and Safety of Spartina® (Tirzepatide Manufactured by CinnaGen) in Patients With Obesity and Overweight
Source: ClinicalTrials.gov · Last updated 15 Jul 2026
Brief summary (registry, in English)
The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered: 1. Is Spartina® (Tirzepatide) effective in the treatment of obesity and overweight? 2. Is Spartina® (Tirzepatide) safe in the treatment of obesity and overweight? In this study, there is no comparison group. Participants receive Spartina® (Tirzepatide)
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 175 (actual)
- First submitted
- 23 Nov 2025
- Start date
- 11 Nov 2025
- Primary completion date
- 20 Jun 2026
- Lead sponsor
- Cinnagen
- Diseases
- Obesity
- NCT number
- NCT07262762
What you commit to
- Study type: Observational
- Participants enrolled: 175
- From 11 Nov 2025 to the primary completion date, 20 Jun 2026
- 14 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior use of any GLP-1 agonist in the last 6 months
Other illness
- Type 1 diabetes mellitus
- Any condition or circumstance that might pose a risk to the subject or interfere with the ability to acquire satisfactory clinical data
- Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
Other
- Pregnancy or breast-feeding
Who the study is looking for
- Male or female ≥18 years of age
- Willingness for signing and having signed the informed consent form
- BMI ≥30 kg/m² or ≥27 kg/m² with ≥1 weight-related comorbidity
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (14)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hajieh Bibi Shahbazian Clinic Coordinator of this site? Confirm its status | Ahvāz | Iran | Unknown status |
| Mansoor Siavash Dastjerdi Clinic Coordinator of this site? Confirm its status | Isfahan | Iran | Unknown status |
| Shokoofeh Bonakdaran Clininc Coordinator of this site? Confirm its status | Mashhad | Iran | Unknown status |
| Behrang Motamed Clinic Coordinator of this site? Confirm its status | Rasht | Iran | Unknown status |
| Seyed Mojtaba Mehrdad Clinic Coordinator of this site? Confirm its status | Rasht | Iran | Unknown status |
| Sari Diabetes Research Center Coordinator of this site? Confirm its status | Sari | Iran | Unknown status |
| Dr. Mohammadhossein Dabbaghmanesh Clinic Coordinator of this site? Confirm its status | Shiraz | Iran | Unknown status |
| Akbar Aliasgarzadeh Clinic Coordinator of this site? Confirm its status | Tabriz | Iran | Unknown status |
| Alireza Esteghamati clinic Coordinator of this site? Confirm its status | Tehran | Iran | Unknown status |
| Iran University Endocrinology Research Center Coordinator of this site? Confirm its status | Tehran | Iran | Unknown status |
| Mohammadreza Mohajeri Tehrani Clininc Coordinator of this site? Confirm its status | Tehran | Iran | Unknown status |
| Farzad Hadaegh Clininc Coordinator of this site? Confirm its status | Tehran | Iran | Unknown status |
| Imam Khomeini Hospital Coordinator of this site? Confirm its status | Tehran | Iran | Unknown status |
| Khorshid Clinic Coordinator of this site? Confirm its status | Yazd | Iran | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.